127 related articles for article (PubMed ID: 16574490)
1. Dendritic cell-based tumor vaccines and antigen presentation attenuators.
Evel-Kabler K; Chen SY
Mol Ther; 2006 May; 13(5):850-8. PubMed ID: 16574490
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of antigen-presentation attenuators to augment vaccines.
Evel-Kabler K; Chen SY
Curr Opin Mol Ther; 2006 Feb; 8(1):24-30. PubMed ID: 16506522
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
Kang TH; Lee JH; Bae HC; Noh KH; Kim JH; Song CK; Shin BC; Hung CF; Wu TC; Park JS; Kim TW
Immunol Lett; 2006 Aug; 106(2):126-34. PubMed ID: 16844231
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells from bench to bedside and back.
Adema GJ
Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based cancer immunotherapies.
Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
7. Reengineering dendritic cell-based anti-cancer vaccines.
Koski GK; Cohen PA; Roses RE; Xu S; Czerniecki BJ
Immunol Rev; 2008 Apr; 222():256-76. PubMed ID: 18364007
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
9. Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency.
Kang TH; Bae HC; Kim SH; Seo SH; Son SW; Choi EY; Seong SY; Kim TW
J Gene Med; 2009 Oct; 11(10):889-98. PubMed ID: 19618483
[TBL] [Abstract][Full Text] [Related]
10. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with dendritic cells for cancer.
Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
[TBL] [Abstract][Full Text] [Related]
12. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses.
Du YC; Lin P; Zhang J; Lu YR; Ning QZ; Wang Q
Tissue Antigens; 2006 May; 67(5):368-76. PubMed ID: 16671943
[TBL] [Abstract][Full Text] [Related]
13. Exploiting dendritic cells for active immunotherapy of cancer and chronic infection.
O'Neill D; Bhardwaj N
Methods Mol Med; 2005; 109():1-18. PubMed ID: 15585909
[TBL] [Abstract][Full Text] [Related]
14. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
Shojaeian J; Jeddi-Tehrani M; Dokouhaki P; Mahmoudi AR; Ghods R; Bozorgmehr M; Nikoo S; Bayat AA; Akhondi MM; Ostadkarampour M; Rezania S; Zarnani AH
J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973
[TBL] [Abstract][Full Text] [Related]
15. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine.
den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Toonen LW; Figdor CG; Ruers TJ; Adema GJ
Cancer Res; 2006 Jul; 66(14):7285-92. PubMed ID: 16849578
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-based cancer vaccination: quo vadis?
Dauer M; Schnurr M; Eigler A
Expert Rev Vaccines; 2008 Sep; 7(7):1041-53. PubMed ID: 18767953
[TBL] [Abstract][Full Text] [Related]
17. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
[TBL] [Abstract][Full Text] [Related]
18. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
Lynch DH
Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, erbB2.
Xu Y; Darcy PK; Kershaw MH
Cancer Gene Ther; 2007 Sep; 14(9):773-80. PubMed ID: 17599092
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-based immunotherapy.
Osada T; Clay TM; Woo CY; Morse MA; Lyerly HK
Int Rev Immunol; 2006; 25(5-6):377-413. PubMed ID: 17169781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]